GSK’s investigational therapy bepirovirsen has been accepted for Priority Review by the US Food and Drug Administration (FDA) for the treatment of adults with chronic hepatitis B (CHB). The therapy has also been granted Breakthrough Therapy Designation, reflecting its potential to offer substantial improvement over existing treatments.
Bepirovirsen is an antisense oligonucleotide (ASO) designed to target hepatitis B virus (HBV) RNA. The Breakthrough Therapy Designation builds on the Fast Track Designation granted in February 2024, further enabling expedited development and regulatory review.
The regulatory submission is supported by results from the Phase III B-Well clinical trials, which demonstrated statistically significant and clinically meaningful functional cure rates in patients with chronic hepatitis B.
Chronic hepatitis B remains a major global health burden, affecting more than 250 million people worldwide and approximately 1.7 million people in the United States. Current standard-of-care therapies often require lifelong treatment and deliver functional cure rates of around 1%, highlighting the need for more effective options.
The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of 26 October 2026 for its review of bepirovirsen.
From a commercial perspective, if approved, bepirovirsen could represent a first-in-class functional cure approach in chronic hepatitis B, expanding GSK’s presence in liver disease therapeutics. Given the large global patient population and limitations of current therapies, the asset holds potential for significant market opportunity and long-term revenue growth.
